Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis

Citations Over TimeTop 23% of 2012 papers

Abstract

In this model, CP is an acceptable alternative to cisplatin for the treatment of these patients with an increase in cost of only $13,654/QALY. The addition of topotecan did not increase survival enough to justify the increased cost.

Related Papers

• → Review role of topotecan in gynaecological cancers: Current indications and perspectives(2009)62 cited
• → Clinical experience with topotecan in relapsed ovarian cancer(2003)21 cited
• → Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study(2002)6 cited
• → Secondary Response of Ovarian Tumors to Topotecan Treatment(1998)5 cited
• The role of topotecan as second-line chemotherapy in patients with recurrent epithelial ovarian cancer(2005)